2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1

por Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Hyung Kim, Joon, Levin, Myron J, Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L
Publicado 2019

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

por Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Kim, Joon Hyung, Levin, Myron J., Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L.
Publicado 2020

2779. Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-hoc Analysis

por Willer, David O, Wascotte, Valentine, Kim, Joon Hyung, Zahaf, Toufik, Talarico, Carla, Gorfinkel, Iris, Gervais, Pierre, Pharm, Pharm, L, Cunningham, Anthony L, Oostvogels, Lidia, Colindres, Romulo, Schuind, Anne
Publicado 2019